Swiss National Bank Has $172.06 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Swiss National Bank cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 306,000 shares of the biopharmaceutical company’s stock after selling 17,700 shares during the period. Swiss National Bank owned about 0.29% of Regeneron Pharmaceuticals worth $172,055,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. WINTON GROUP Ltd lifted its position in Regeneron Pharmaceuticals by 219.2% in the 3rd quarter. WINTON GROUP Ltd now owns 4,319 shares of the biopharmaceutical company’s stock worth $2,428,000 after buying an additional 2,966 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 31.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 228,828 shares of the biopharmaceutical company’s stock valued at $128,608,000 after acquiring an additional 55,019 shares in the last quarter. Schroder Investment Management Group grew its holdings in shares of Regeneron Pharmaceuticals by 17.0% during the 3rd quarter. Schroder Investment Management Group now owns 25,755 shares of the biopharmaceutical company’s stock valued at $14,481,000 after acquiring an additional 3,750 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $14,358,000. Finally, Pinnacle Associates Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 22.1% in the third quarter. Pinnacle Associates Ltd. now owns 84,191 shares of the biopharmaceutical company’s stock worth $47,338,000 after acquiring an additional 15,265 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Zacks Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Canaccord Genuity Group boosted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. Finally, Cantor Fitzgerald lifted their price target on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Trading Up 2.9%

Shares of NASDAQ:REGN opened at $781.60 on Tuesday. The stock has a market capitalization of $82.63 billion, a PE ratio of 18.81, a P/E/G ratio of 2.04 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The firm has a fifty day moving average price of $770.83 and a 200 day moving average price of $690.73. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the business posted $12.07 earnings per share. The business’s quarterly revenue was up 2.5% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a dividend of $0.94 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is currently 9.05%.

Insider Buying and Selling

In related news, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 5,274 shares of company stock valued at $4,142,738 over the last 90 days. 7.02% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.